GlassScriptPhysician profile
Jennifer Nicholson
NPI 1174831549
$1,032.37
in general payments reported to CMS, 2019-2025
22 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.94 · 2022: $156 · 2023: $182 · 2024: $185 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $189.46 | 2023-2025 | Ninlaro, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $144.29 | 2024-2025 | |
| Janssen Biotech, INC. | $105.07 | 2022-2025 | Erleada |
| Adc Therapeutics America, INC. | $63.36 | 2025 | |
| Puma Biotechnology, INC. | $61.64 | 2022 | |
| Iovance Biotherapeutics, INC. | $60.31 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $53.97 | 2023-2024 | Orserdu |
| Genmab U.S., INC. | $49.48 | 2024-2025 | Epkinly |
| Lilly USA, LLC | $30.49 | 2021-2022 | |
| Foundation Medicine, INC. | $28.24 | 2023 | |
| Allergan, INC. | $26.00 | 2021 | |
| G1 Therapeutics, INC. | $24.90 | 2022 | |
| Merz North America, INC. | $24.70 | 2021 | |
| Rigel Pharmaceuticals, INC. | $24.54 | 2023 | Tavalisse, Rezlidhia |
| Celgene Corporation | $23.25 | 2023 | Opdualag |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.76 | 2022 | |
| Blueprint Medicines Corporation | $19.35 | 2025 | Ayvakit |
| Abbvie INC. | $18.52 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.58 | 2023 | Empaveli |
| Pfizer INC. | $14.70 | 2021 | |
| Urovant Sciences INC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.